As I reported, the phase II trial shows that, depending on the subgroup, patients with inoperable pancreatic cancer have a threefold to sixfold dose related improvement in survival. None of the common toxic effects of chemotherapy for cancer were observed. These dose related effects, the investigators report, are "relatively robust with high degrees of statistical significance." This work seemed to be of great interest, partly because there are no effective treatments for pancreatic cancer and partly because of the lack of toxicity of lithium gammalinolenate given intravenously over two weeks. Readers of the Times were aware ofthis work, even if Petrie was not.
Petrie complains that the article gives the impression that the treatment is a simple dietary supplement. This is not stated or The hypothesis underlying the use of these fatty acids as anti-inflammatory drugs derives from their effects on altering prostaglandin synthesis. They compete with arachidonic acid for the cyclooxygenase and lipooxygenase enzymes and divert prostaglandin production away from the 2 series toward the 3 series (eicosapentaenoic acid) and 1 series (gammalinolenic acid).3 This alteration of prostaglandin synthesis seems to be associated with abrogation of the inflammatory response. The fatty acids have been shown to reduce weight loss significantly in animal cancer models.4 The potential to downregulate the hepatic acute phase response and energy expenditure with fatty acids might increase survival in pancreatic cancer patients who are losing weight. We make the experimental nature of these drugs quite clear to our patients, and, although there is some evidence of in vitro tumour cell killing,5 we emphasise that we consider these treatments to be palliative anticachexia agents. It should also be mentioned that the toxicity profiles of both drugs are significantly better than those associated with conventional chemotherapy, which is an important consideration in patients who have a limited life expectancy.
The overstatement of medical data in the press may serve to undermine the confidence of patients and ofpractitioners responsible for their care. Airline's magazine promotes production oftobacco products EDITOR,-During a recent British Airways flight we were appalled to read, in the company's Business Life magazine, an article celebrating the profits to be made from producing tobacco products in eastem Europe.' The article described in glowing terms how one entrepreneur had negotiated a licence to produce tobacco products in an eastern European country and, through careful tax planning, had enabled profits to be brought back to western Europe.
Perhaps British Airways is not aware that mortality and morbidity in eastern Europe are increasing and that one of the main reasons for this is the increase in cigarette smoking. Furthermore, health care services in the new democracies have been severely weakened by reduced tax receipts, and this has contributed to the increase in mortality.' The ethics of encouraging the production of tobacco products and (albeit legal) minimising of tax are therefore dubious. We expect better from "the world's favourite airline." An editorial error occurred in this letter by P D Thomas (2 July, pp 534). The last line of the letter should read, "It now seems that pharmacists in maintenance programmes have far more to offer than doctors concemed, so perhaps we will soon hear of the deregulation of methadone to pharmacy list status."
